

Understanding PSMA PET Imaging in Prostate Cancer

Join us on April 26 at 2:30 PM to 3:15 PM, Booth #2001, Product Theater, in the Science and Technology Hall



Mark Fallick, MD, MBA, FACS

Urologist

Senior Medical Director, Radioligand Therapy
Novartis Pharmaceuticals Corporation

Session Contents:

- Overview of imaging modalities in prostate cancer with a focus on PET/CT
- Radioligand imaging in prostate cancer, its mechanism of action, and uses based on current guidelines and consensus
- Impact of PSMA PET on staging of prostate cancer and management of biochemically recurrent disease, hormone-sensitive and castration-resistant prostate cancer

The Novartis RLT Institute
Explore tools and practical
considerations for integrating
our RLTs into your practice

